期刊文献+

Evaluation of treatment response for breast cancer:are we entering the era of "biological complete remission"? 被引量:3

Evaluation of treatment response for breast cancer:are we entering the era of “biological complete remission”?
在线阅读 下载PDF
导出
摘要 Breast cancer is one of the most common malignancies in women. The post-operative recurrence and metastasis are the leading causes of breast cancer-related mortality. In this study, we tried to explore the role of circulating tumor cell (CTC) detection combination PET/CT technology evaluating the prognosis and treatment response of patients with breast cancer; meanwhile, we attempted to assess the concept of "biological complete remission" (bCR) in this regard. A 56-year-old patient with breast cancer (T2N1M1, stage IV left breast cancer, with metastasis to axillary lymph nodes and lungs) received 6 cycles of salvage treatment with albumin-bound paditaxd plus eapecitaabine and trastuzumah. Then, she underwent CTC detection and PET/CT for efficacy evaluation. CTC detection combination PET/CT is useful for the evaluation of the biological efficacy of therapies for breast cancer. The bCR of the patient appeared earlier than the conventional clinical imaging complete remission and promised the histological (pathological) complete remission. The integrated application of the concepts including bCR, imageological CR, and histological CR can achieve the early and prognosis of breast cancer. accurate assessment of biological therapeutic reponse and Breast cancer is one of the most common malignancies in women. The post-operative recurrence and metastasis are the leading causes of breast cancer-related mortality. In this study, we tried to explore the role of circulating tumor cell (CTC) detection combination PET/CT technology evaluating the prognosis and treatment response of patients with breast cancer; meanwhile, we attempted to assess the concept of "biological complete remission" (bCR) in this regard. A 56-year-old patient with breast cancer (T2N1M1, stage IV left breast cancer, with metastasis to axillary lymph nodes and lungs) received 6 cycles of salvage treatment with albumin-bound paditaxd plus eapecitaabine and trastuzumah. Then, she underwent CTC detection and PET/CT for efficacy evaluation. CTC detection combination PET/CT is useful for the evaluation of the biological efficacy of therapies for breast cancer. The bCR of the patient appeared earlier than the conventional clinical imaging complete remission and promised the histological (pathological) complete remission. The integrated application of the concepts including bCR, imageological CR, and histological CR can achieve the early and prognosis of breast cancer. accurate assessment of biological therapeutic reponse and
出处 《Chinese Journal of Cancer Research》 SCIE CAS CSCD 2012年第4期403-407,共5页 中国癌症研究(英文版)
基金 supported by the department of pathology and the PET/CT center of Affiliated Hospital of Academy of Military Medical Sciences
关键词 Breast cancer circulating tumor cell PET/CT biological complete remission Breast cancer circulating tumor cell PET/CT biological complete remission
作者简介 Corresponding to: Ze-Fei Jiang. Department of Breast Cancer, Affiliated Hospital of Academy of Military Medical Sciences, No.8 Dongda Street, Fengtai District, Beijing, China. Email: jiangzefei@medmail.com.cn.
  • 相关文献

参考文献16

  • 1Campbell JB. Breast cancer-race, ethnicity, and survival: a literature review. Breast Cancer Res Treat 2002;74:187-92.
  • 2Veronesi U, Salvadori B, Luini A, et al. Conservative treatment of early breast cancer. Long-term results of 1232 cases treated with quadrantectomy, axillary dissection, and radiotherapy. Ann Surg 1990;211:250-9.
  • 3Mocellin S, Keilholz U, Rossi CR, et al. Circulating tumor cells: the 'leukemic phase' of solid cancers. Trends Mol Med 2006;12:130-9.
  • 4Cristofanilli M, Budd GT, Ellis MJ, et al. Circulating tumor ceils, disease progression, and survival in metastatic breast cancer. N EnglJ Med 2004;351:781-91.
  • 5De Giorgi U, Valero V, Rohren E, et al. Circulating tumor cells and [18F]fluorodeoxyglucose positron emission tomography/computed tomography for outcome prediction in metastatic breast cancer. J Clin Oncol 2009;27:3303-11.
  • 6Giannopoulou C. The role of SPET and PET in monitoring tumour response to therapy. Eur J Nucl Med Mol Imaging 2003;30:1173-200.
  • 7Dose-Schwarz J, Tiling R, Avril-Sassen S, et al. Assessment of residual tumour by FDG-PET: conventional imaging and clinical examination following primary chemotherapy of large and locally advanced breast cancer. Br J Cancer 2010;102:35-41.
  • 8Tiruppathi C, Finnegan A, Malik AB. Isolation and characterization of a cell surface albumin-binding protein from vascular endothelial cells. Proc Natl Acad Sci U S A 1996;93:250-4.
  • 9Desai NE Trieu V,, Hwang LY, et al. Improved effectiveness of nanoparticle albumin-bound (nab) paclitaxel versus polysorbate-based docetaxel in multiple xenografts as a function of HER2 and SPARC status. Anticancer Drugs 2008;19:899-909.
  • 10Talbot DC, Moiseyenko V,, Van Belle S, et al. Randomised, phase Ⅱ trial comparing oral capecitabine (Xeloda) with paclitaxel in patients with metastatic/advanced breast cancer pretreated with anthracyclines. BrJ Cancer 2002;86:1367-72.

同被引文献8

引证文献3

二级引证文献21

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部